In Phase 3 TRIUMPH-1 data, diarrhea was reported in 25.2% to 34.1% of participants taking retatrutide, constipation in 23.8% to 26.1%, and vomiting in 10.6% to 25.3%, compared with lower rates among participants receiving placebo
[DOI] [PubMed] [Google Scholar] 113.Lieske J.C., Kumar R., Collazo-Clavell M.L
pharmacy Refund available if you do not qualify, subject to program terms Select a Payment Option for Your 12-week Treatment: PAY MONTHLY NEW LOW PRICE PAY IN FULL AND SAVE NEW LOW PRICE Price varies based on final dosage
In a clinical trial, the highest dose of orforglipron led to 11.2 percent weight loss at 72 weeks
For most healthy adults, human studies from 2020 to 2024 indicate Pendulum-brand products are generally well tolerated, with mostly mild gastrointestinal complaints that tend to be transient
Obesity 30(4):841857 Coulter AA, Rebello CJ, Greenway FL (2018) Centrally acting drugs for obesity: past, present, and future